A case report of mesalazine-induced lung injury: A reversible drug side effect

[1]  R. Russell,et al.  European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease , 2017, Journal of Crohn's & colitis.

[2]  H. Tilg,et al.  The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[3]  M. Bando,et al.  Drug-induced Hypersensitivity Syndrome Accompanied by Pulmonary Lesions Exhibiting Centrilobular Nodular Shadows. , 2016, Internal medicine.

[4]  May Y. Choi,et al.  Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement , 2015, Inflammatory bowel diseases.

[5]  J. Kuś,et al.  Pulmonary pathology in patients with ulcerative colitis treated with mesalazine--a challenging and complex diagnostic problem. Case series and literature review. , 2014, Pneumonologia i alergologia polska.

[6]  O. Matsuno,et al.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches , 2012, Respiratory Research.

[7]  P. Mergo,et al.  Mesalamine-Related Lung Disease: Clinical, Radiographic, and Pathologic Manifestations , 2003, Inflammatory bowel diseases.

[8]  M. Brezina,et al.  Pulmonary complications in patients with inflammatory bowel disease. , 1999, Hepato-gastroenterology.

[9]  A. Bitton,et al.  Mesalamine-induced lung toxicity. , 1996, The American journal of gastroenterology.

[10]  V. Le Gros,et al.  Lung and skin hypersensitivity to 5-aminosalicylic acid. , 1991, BMJ.